X
Wedesday, July 9, 2025
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

DHL Supply Chain comes up with New Pharma Hub in Singapore

API PA by API PA
19th April 2025
in News
DHL Supply Chain

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

DHL Supply Chain, which happens to be a German contract logistics service provider, has gone on to launch a novel pharma hub in Singapore. This kind of dedicated facility when it comes to pharmaceutical logistics goes to represent an investment worth $11.37 billion.

This facility is a part of the DHL Group’s broader $568 million commitment when it comes to enhancing its life sciences and healthcare infrastructure throughout all business units across Asia Pacific. It also goes on to depict the firms within healthcare sector as a part of its strategy 2030. Apparently, the life sciences and healthcare infrastructure at present generates $5.68 billion for the global revenue of DHL, thereby highlighting its prominence when it comes to the group’s growth strategy.

The new pharma hub in Singapore, which extends to 8200 km² in Singapore, goes on to feature temperature-controlled areas, thereby creating perfect conditions in order to store delicate medical supplies. This facility, which adheres to the good manufacturing practice – GMP also has in it an advanced cold storage infrastructure like airtight loading docks along with specialized anterooms that make sure of a temperature stability all throughout the transportation process which is consistent in nature.

As per the CEO of Asia Pacific for DHL Supply Chain, Javier Bilbao, their investment goes much beyond building only warehouses or expanding network. It is more like coming up with a robust foundation throughout all the business units that enables faster along with a more dependable delivery when it comes to lifesaving medicines and healthcare products. He adds that in the region where healthcare demand happens to be increasing, they help their customers to stress innovation and, thereby, at the end of the day, patient care.

He further went on to add that at the same time, they handle the intricacies when it comes to supply chain management throughout the logistic touchpoints, right from storage and order fulfillment to spreading throughout worldwide shipping and also last-mile delivery. And that is how they go on to deliver real value by way of turning barriers into opportunities and making sure that every link within the healthcare supply chain works as seamlessly as possible.

It is well to be noted that the pharma hub in Singapore is based at Tuas Bio-Medical Park, hence offering a convenient access to both Tuas Mega Port and Changi Airport in order to elevate distribution capacities for its pharmaceutical partners, both in the region and across the world.

Furthermore, DHL Group has also announced a worldwide investment of $2.27 billion by the end of the decade in order to enhance the integrated healthcare solutions. Apart from this, it has recently acquired CRYOPDP, which is a specialty courier offering end-to-end temperature control solutions and also services that are customized for the life sciences and healthcare sector.

Tags: Featured
Previous Post

Digital Twins in Biopharma: Innovation in Manufacturing

Next Post

AI Revolutionizing Drug Discovery and Clinical Development

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
Clinical Development

AI Revolutionizing Drug Discovery and Clinical Development

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Notifications